Hopp Biotech News Today

Key Insights The considerable ownership by private equity firms in CureVac indicates that they collectively have a...

Key Insights Significantly high institutional ownership implies Immatics' stock price is sensitive to their trading...

CureVac N.V. Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income ...

VEVYE® is the First and Only Cyclosporine-Based Product Indicated for the Treatment of Both Signs and Symptoms of Dry Eye Disease with Efficacy Demonstrated After Four WeeksVEVYE® is the Only Water-Free Ophthalmic Product with Convenient Twice-Daily (BID) DosingNASHVILLE, Tenn. & HEIDELBERG, Germany--(BUSINESS WIRE)...

Key Insights The considerable ownership by private equity firms in AC Immune indicates that they collectively have a...

Key Insights The considerable ownership by private companies in Cosmo Pharmaceuticals indicates that they collectively...

VEVYE is the first and only cyclosporine solution indicated for the treatment of signs and symptoms of dry eye disease with efficacy demonstrated after 4 weeks Novaliq GmbH, a biopharmaceutical company

MIEBO is the First and Only Prescription Eye Drop Approved for Dry Eye Disease that Directly Targets Tear Evaporation, Based on Consistent Results from Two Consecutive Pivotal Phase 3 Trials Bausch

Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced the presentation of new data on the investigational

EQS-News: Heidelberg Pharma AG / Key word(s): Interim Report Heidelberg Pharma AG: Interim Management Statement on the First Three Mo...